PTEN and hepatocellular carcinoma: Inactivating PTEN mutations were prevalent in melanoma (10%), hepatocellular carcinoma (13%), squamous cell carcinoma of the lung (15%), glioblastoma multiforme (29%) and uterine carcinoma (66%) and their presence would result in eligibility for early studies of PI3Kβ inhibition23.